CA2456814A1 - Utilisation d'extraits de larves de mouches pour traiter des plaies - Google Patents
Utilisation d'extraits de larves de mouches pour traiter des plaies Download PDFInfo
- Publication number
- CA2456814A1 CA2456814A1 CA002456814A CA2456814A CA2456814A1 CA 2456814 A1 CA2456814 A1 CA 2456814A1 CA 002456814 A CA002456814 A CA 002456814A CA 2456814 A CA2456814 A CA 2456814A CA 2456814 A1 CA2456814 A1 CA 2456814A1
- Authority
- CA
- Canada
- Prior art keywords
- fly
- larval extract
- larvae
- extract
- employed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000284 extract Substances 0.000 title claims abstract description 67
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 60
- 206010052428 Wound Diseases 0.000 title claims abstract description 58
- 230000001684 chronic effect Effects 0.000 claims abstract description 11
- 230000001154 acute effect Effects 0.000 claims abstract description 10
- 241000257162 Lucilia <blowfly> Species 0.000 claims abstract description 7
- 241000257190 Sarcophaga <genus> Species 0.000 claims abstract description 7
- 230000000699 topical effect Effects 0.000 claims abstract description 6
- 238000001816 cooling Methods 0.000 claims abstract description 3
- 230000001418 larval effect Effects 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 12
- 238000000265 homogenisation Methods 0.000 claims description 11
- 239000000470 constituent Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 241000736227 Lucilia sericata Species 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241000257163 Calliphora vicina Species 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 241000257159 Musca domestica Species 0.000 claims description 4
- 241000304160 Sarcophaga carnaria Species 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 230000019617 pupation Effects 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 241000257160 Calliphora Species 0.000 claims description 3
- 241000257166 Lucilia cuprina Species 0.000 claims description 3
- 241000257229 Musca <genus> Species 0.000 claims description 3
- 241001494139 Stomoxys Species 0.000 claims description 3
- 241001494115 Stomoxys calcitrans Species 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000003792 electrolyte Substances 0.000 claims description 3
- 230000029142 excretion Effects 0.000 claims description 3
- 239000000416 hydrocolloid Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000012460 protein solution Substances 0.000 claims description 3
- 239000012266 salt solution Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 238000010410 dusting Methods 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims 1
- 239000011505 plaster Substances 0.000 claims 1
- 230000029663 wound healing Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 4
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 239000002674 ointment Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 108010016297 plasmin drug combination deoxyribonuclease Proteins 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001804 debridement Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000035752 proliferative phase Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 208000005230 Leg Ulcer Diseases 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- -1 fibrolysin Proteins 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000001045 maggot therapy Methods 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 239000004821 Contact adhesive Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000669 biting effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000007556 vascular defect Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne l'application topique d'extraits de larves de mouches, obtenus à partir de larves de mouches qui sont tuées, transformées en extraits à des conditions de refroidissement en milieu aqueux ou dans des solvants, et dépourvues des composés non dissouts. Différents types d'extraits de larves de mouches sont conçus pour traiter des plaies superficielles ou des plaies profondes, chroniques et aiguës, quelle qu'en soit l'origine. Les extraits de larves de mouches présentant un pouvoir de guérison des plaies peuvent par exemple être produits à partir de larves de mouches du genre Sarcophaga ou Lucilia.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10138303A DE10138303A1 (de) | 2001-08-10 | 2001-08-10 | Verwendung von Enzymisolaten aus Fliegenlarven zur Wundbehandlung |
| DE10138303.7 | 2001-08-10 | ||
| DE10149153A DE10149153A1 (de) | 2001-10-04 | 2001-10-04 | Verwendung von Enzymisolaten aus Fliegenlarven zur Wundbehandlung |
| DE10149153.0 | 2001-10-04 | ||
| PCT/EP2002/008497 WO2003013557A1 (fr) | 2001-08-10 | 2002-07-31 | Utilisation d'extraits de larves de mouches pour traiter des plaies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2456814A1 true CA2456814A1 (fr) | 2003-02-20 |
Family
ID=26009873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002456814A Abandoned CA2456814A1 (fr) | 2001-08-10 | 2002-07-31 | Utilisation d'extraits de larves de mouches pour traiter des plaies |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1434591A1 (fr) |
| JP (1) | JP2005501078A (fr) |
| CA (1) | CA2456814A1 (fr) |
| IL (1) | IL160274A0 (fr) |
| MX (1) | MXPA04000298A (fr) |
| WO (1) | WO2003013557A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205593D0 (en) * | 2002-03-09 | 2002-04-24 | Univ Nottingham | Treatment of surfaces populated by bacteria |
| DE102005061246A1 (de) * | 2005-12-20 | 2007-06-28 | Alpha-Biocare Gmbh | Präparate mit niedermolekularen Substanzen aus Dipteren zur Behandlung von Wunden |
| JP4998999B2 (ja) * | 2007-09-11 | 2012-08-15 | 国立大学法人 岡山大学 | ウジムシ治療用のカバードレッシング |
| CN102008003A (zh) * | 2010-12-14 | 2011-04-13 | 韦秀凤 | Md昆虫活性蛋白中间体的提取方法 |
| CN104884068B (zh) * | 2012-07-27 | 2017-11-07 | 株式会社爱南自由 | 多醣类、含有多醣类的组合物、以及免疫赋活剂 |
| KR101808028B1 (ko) | 2016-08-10 | 2017-12-12 | 대한민국(농촌진흥청장) | 습식분쇄법 및 분무건조법을 이용한 갈색거저리 유충의 분말 제조방법 |
| EP3578052B1 (fr) * | 2018-06-05 | 2026-05-06 | Bühler AG | Traitement de larves d`insectes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5913730A (ja) * | 1982-07-15 | 1984-01-24 | Wakunaga Seiyaku Kk | 抗菌性蛋白、その製造法およびその用途 |
| JPS63164895A (ja) * | 1986-09-13 | 1988-07-08 | Sanwa Kagaku Kenkyusho Co Ltd | 培養細胞由来のレクチン様蛋白質及びその製法並びに該物質を主成分とする抗腫瘍剤 |
| JPS63243099A (ja) * | 1987-03-30 | 1988-10-07 | Sanwa Kagaku Kenkyusho Co Ltd | 抗菌性ポリペプチド |
-
2002
- 2002-07-31 EP EP02794527A patent/EP1434591A1/fr not_active Withdrawn
- 2002-07-31 IL IL16027402A patent/IL160274A0/xx unknown
- 2002-07-31 MX MXPA04000298A patent/MXPA04000298A/es unknown
- 2002-07-31 CA CA002456814A patent/CA2456814A1/fr not_active Abandoned
- 2002-07-31 JP JP2003518564A patent/JP2005501078A/ja not_active Withdrawn
- 2002-07-31 WO PCT/EP2002/008497 patent/WO2003013557A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1434591A1 (fr) | 2004-07-07 |
| MXPA04000298A (es) | 2004-05-04 |
| WO2003013557A1 (fr) | 2003-02-20 |
| JP2005501078A (ja) | 2005-01-13 |
| WO2003013557A8 (fr) | 2004-02-26 |
| IL160274A0 (en) | 2004-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2308954C2 (ru) | Фармацевтическая композиция для лечения ран, содержащая плазму или сыворотку крови | |
| Genecov et al. | A controlled subatmospheric pressure dressing increases the rate of skin graft donor site reepithelialization | |
| Knottenbelt | Equine wound management: are there significant differences in healing at different sites on the body? | |
| Paul | Advances in wound healing materials | |
| EA029443B1 (ru) | Фармацевтическая композиция на основе лизата тромбоцитов | |
| US20030124199A1 (en) | Use of fly larval extracts for wound treatment | |
| CN110538312A (zh) | 一种皮肤创伤修复软膏及其制备方法 | |
| ES2467668T3 (es) | Composicón farmaceutica, vendaje y método para tratar lesión cutánea, composición intermedia y proceso para preparar dicho vendaje y uso de sal de cerio asociada con una matriz de colágeno | |
| JP7026050B2 (ja) | 慢性創傷を治療するための組成物及び方法 | |
| Kogan et al. | Biologics in acute burn injury | |
| KR20010012952A (ko) | 화상과 여러 피부 외상의 치료를 위한 수단 및 조성물 | |
| NZ202259A (en) | Wound healing composition,preparation and uses | |
| JP4726300B2 (ja) | 移植用マトリックス・タンパク質組成物 | |
| JP2005501078A (ja) | 創傷治療のためのハエ幼虫の抽出物の使用 | |
| EP0215274B1 (fr) | Extraits de cellules épidermiques et procédé pour améliorer la guérison des plaies et pour régénérer l'épiderme | |
| Arámbula et al. | Frozen human epidermal allogeneic cultures promote rapid healing of facial dermabrasion wounds | |
| US20080102106A1 (en) | Wound Healing Composition Comprising Substances From Diptera Larvae | |
| Kierski et al. | Novel extracellular matrix wound dressing shows increased epithelialization of full-thickness skin wounds in dogs | |
| Price et al. | Skin repair technology | |
| Hamilton et al. | Efficiency of enzymatic debridement in the healing process of chronic wounds in small animal practice | |
| US20090285906A1 (en) | Preparation Made From Diptera Larvae For The Treatment Of Wounds | |
| DE10138303A1 (de) | Verwendung von Enzymisolaten aus Fliegenlarven zur Wundbehandlung | |
| DE10327489B4 (de) | Verwendung von Bestandteilen von Dipteren-Puppen zur Behandlung von Wunden | |
| DE10149153A1 (de) | Verwendung von Enzymisolaten aus Fliegenlarven zur Wundbehandlung | |
| KR20200060997A (ko) | 창상치료용 약학조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |